BBI Group acquires DIARECT AG

BBI Group, the world’s leading independent provider of immuno-diagnostic reagents and contract services, has acquired DIARECT, a leading supplier of autoimmune antigen products.

The acquisition enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier and boosts BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

The UK-based business, which has manufacturing sites and sales offices across four continents, will integrate DIARECT’s state of the art manufacturing facility in Germany, to establish a Centre of Excellence for recombinant antigen development and manufacturing in Freiburg.

The combined capability enables BBI to further service high growth disease segments such as cancer, cardiac conditions and diabetes, while also enable BBI to drive geographic expansion for DIARECT, which will benefit from a bigger sales force.